Intensive glucose control compared with standard therapy in type 2 diabetes: A systemic review

Chinese Journal of Evidence-Based Medicine

Volumn 9, Issue 7, 2009, Pages 774-782

  Wang, Qian ^a   Han, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Intensive glucose control; Systematic review; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE;

CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; EMBASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MEDLINE; META ANALYSIS; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 70349310355     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. American diabetes association. Standards of Medical Care in Diabetes-2009. Diabetes Care, 2009, 32(suppl1): s13-s61.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15(7): 539-553.
3. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care, 2007, 30(Suppl 1): S4-S41.
4. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17: 1-12.
5. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21: 1539-1558.
6. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327: 557-560.
7. Egger M, Altman DG, Smith GD. Systematic reviews in health-care: meta-analysis in context. 2nd edn. BMJ Books, Wiley: London, 2001.
8. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360(2): 129-139.
9. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358(24):2545-2559.
10. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008, 358(24):2560-2572. (Pubitemid 351831357)
11. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med, 2007, 357(1): 28-38. (Pubitemid 47026732)
12. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366(9493): 1279-1289. (Pubitemid 41416583)
13. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348(5): 383-393. (Pubitemid 36159355)
14. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 2000, 23 Suppl 2: B21-B29. (Pubitemid 30185774)
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352: 837-853.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329: 977-986.
17. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J, 2000, 321: 405-412. (Pubitemid 30609442)
18. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359(15): 1577-1589.
19. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 22:2643-2653 (Pubitemid 41817713)
20. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care, 2009, 32(1): 187-192.